GH, CARDIOVASCULAR RISK AND VISCERAL ADIPOSITY IN WOMEN

GH、女性心血管风险和内脏肥胖

• 批准号: 7731318
• 负责人: Karen K Miller
• 金额: $ 0.23万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731318
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Dose; Fatty acid glycerol esters; Funding; Grant; Hormone replacement therapy; Institution; Obesity; Population; Purpose; Recombinant Growth Hormone; Relative (related person); Research; Research Personnel; Resources; Risk Marker; Somatotropin; Source; Testing; United States National Institutes of Health; Visceral; Weight; Woman; cardiovascular risk factor; growth hormone deficiency; heart disease risk

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study examines women who have both high levels of belly fat and low levels of growth hormone (GH). The purpose of the study is to investigate whether GH replacement therapy reduces belly fat in this population. Since belly fat is associated with an increased risk for heart disease, we are also studying whether GH replacement therapy reduces the risk of heart disease in this population. Specific Aims - The following hypotheses will be tested: Specific Aim 1: Women with visceral adiposity have reduce growth hormone (GH) secretion, which is associated with increased cardiovascular risk. We will investigate in women with visceral adiposity whether: A. Growth hormone secretion is reduced compared with 1) normal-weight women and 2) BMI-matched women who do not have visceral adiposity b. Reduced growth hormone secretion is associated with increases in cardiovascular risk markers. Specific Aim 2: Administration of low dose recombinant GH for six months to women with visceral adiposity and relative growth hormone deficiency will result in reduced visceral fat mass and improvements in markers of cardiovascular risk.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这项研究调查了腹部脂肪含量高且生长激素 (GH) 水平低的女性。 该研究的目的是调查 GH 替代疗法是否可以减少该人群的腹部脂肪。 由于腹部脂肪与心脏病风险增加有关，我们还在研究 GH 替代疗法是否可以降低该人群患心脏病的风险。 具体目标 - 将测试以下假设： 具体目标 1：内脏肥胖的女性生长激素 (GH) 分泌减少，这与心血管风险增加相关。 我们将调查患有内脏肥胖的女性是否： A. 与 1) 正常体重女性和 2) BMI 匹配但没有内脏肥胖的女性相比，生长激素分泌减少 b.生长激素分泌减少与心血管风险标志物增加有关。 具体目标 2：对内脏肥胖和相对生长激素缺乏的女性施用低剂量重组 GH 六个月，将导致内脏脂肪量减少并改善心血管风险标志物。